Inflammatory signaling and aryl hydrocarbon receptor mediate synergistic induction of interleukin 6 in MCF-7 cells

Cancer Research

Volumn 68, Issue 10, 2008, Pages 3609-3617

  Hollingshead, Brett D ^a   Beischlag, Timothy V ^a,b   DiNatale, Brett C ^a   Ramadoss, Preeti ^a   Perdew, Gary H ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b SIMON FRASER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450 1A1; INTERLEUKIN 1BETA; INTERLEUKIN 6; PHORBOL 13 ACETATE 12 MYRISTATE; LIGAND; MESSENGER RNA; RNA;

ARTICLE; CELL STRAIN MCF 7; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INFLAMMATION; PLEIOTROPY; PRIORITY JOURNAL; PROMOTER REGION; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; BIOLOGICAL MODEL; CELL DIFFERENTIATION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; METABOLISM; TUMOR CELL LINE;

CELL DIFFERENTIATION; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; LIGANDS; MODELS, BIOLOGICAL; RECEPTORS, ARYL HYDROCARBON; RNA; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 45549093658     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-6168     Document Type: Article

References (50)

1. Nebert DW, Robinson JR, Niwa A, Kumaki K, Poland AP. Genetic expression of aryl hydrocarbon hydroxylase activity in the mouse. J Cell Physiol 1975;85:393-414.
2. Burbach KM, Poland A, Bradfield CA. Cloning of the Ah-receptor cDNA reveals a distinctive ligand-activated transcription factor. Proc Natl Acad Sci U S A 1992;89:8185-9.
3. Davis BJ, McCurdy EA, Miller BD, Lucier GW, Tritscher AM. Ovarian tumors in rats induced by chronic 2,3,7,8-tetrachlorodibenzo-p-dioxin treatment. Cancer Res 2000;60:5414-9.
4. Watson MA, Devereux TR, Malarkey DE, Anderson MW, Maronpot RR. H-ras oncogene mutation spectra in B6C3F1 and C57BL/6 mouse liver tumors provide evidence for TCDD promotion of spontaneous and vinyl carbamate-initiated liver cells. Carcinogenesis 1995;16:1705-10.
5. Poland A, Palen D, Glover E. Tumour promotion by TCDD in skin of HRS/J hairless mice. Nature 1982;300:271-3.
6. Moennikes O, Loeppen S, Buchmann A, et al. A constitutively active dioxin/aryl hydrocarbon receptor promotes hepatocarcinogenesis in mice. Cancer Res 2004;64:4707-10.
7. Bock KW, Kohle C. Ah receptor- and TCDD-mediated liver tumor promotion: clonal selection and expansion of cells evading growth arrest and apoptosis. Biochem Pharmacol 2005;69:1403-8.
8. Pocar P, Fischer B, Klonisch T, Hombach-Klonisch S. Molecular interactions of the aryl hydrocarbon receptor and its biological and toxicological relevance for reproduction. Reproduction 2005;129:379-89.
9. Tian Y, Rabson AB, Gallo MA. Ah receptor and NF-κB interactions: mechanisms and physiological implications. Chem Biol Interact 2002;141:97-115.
10. Camacho IA, Singh N, Hegde VL, Nagarkatti M, Nagarkatti PS. Treatment of mice with 2,3,7,8-tetrachlorodibenzo-p-dioxin leads to aryl hydrocarbon receptor-dependent nuclear translocation of NF-κB and expression of Fas ligand in thymic stromal cells and consequent apoptosis in T cells. J Immunol 2005;175:90-103.
11. Ke S, Rabson AB, Germino JF, Gallo MA, Tian Y. Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-α and lipopolysaccharide. J Biol Chem 2001;276:39638-44.
12. Jensen BA, Leman RJ, Schlezinger JJ, Sherr DH. Aryl hydrocarbon receptor (AhR) agonists suppress interleukin-6 expression by bone marrow stromal cells: an immunotoxicology study. Environ Health Perspect 2003;2:16.
13. Krueger JG, Krane JF, Carter DM, Gottlieb AB. Role of growth factors, cytokines, and their receptors in the pathogenesis of psoriasis. J Invest Dermatol 1990;94:135-40S.
14. Sugawara T, Gallucci RM, Simeonova PP, Luster MI. Regulation and role of interleukin 6 in wounded human epithelial keratinocytes. Cytokine 2001;15:328-36.
15. Hama T, Miyamoto M, Tsukui H, Nishio C, Hatanaka H. Interleukin-6 as a neurotrophic factor for promoting the survival of cultured basal forebrain cholinergic neurons from postnatal rats. Neurosci Lett 1989;104:340-4.
16. Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression. Prostate 2007;67:764-73.
17. Conze D, Weiss L, Regen PS, et al. Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells. Cancer Res 2001;61:8851-8.
18. Cavarretta IT, Neuwirt H, Untergasser G, et al. The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 2007;26:2822-32.
19. Tartour E, Sastre-Garau X, Pannetier C, Mosseri V, Kourilsky P, Fridman WH. Analysis of interleukin 6 gene expression in cervical neoplasia using a quantitative polymerase chain reaction assay: evidence for enhanced interleukin 6 gene expression in invasive carcinoma. Gynecol Oncol 1994;54:6243-8.
20. Takano H, Harigaya K, Ishii G, et al. Interleukin-6 (IL-6) production in carcinoma of the cervix. Arch Gynecol Obstet 1996;258:25-33.
21. Tjiong MY, van der Vange N, ten Kate FJ, et al. Increased IL-6 and IL-8 levels in cervicovaginal secretions of patients with cervical cancer. 1999;73:285-91.
22. Knupfer H, Preiss R. Significance of interleukin-6 (IL-6) in breast cancer [review]. Breast Cancer Res Treat 2007;102:129-35.
23. Basolo F, Conaldi PG, Fiore L, Calvo S, Toniolo A. Normal breast epithelial cells produce interleukins 6 and 8 together with tumor-necrosis factor: defective IL6 expression in mammary carcinoma. Int J Cancer 1993;55:926-30.
24. Sasser AK, Sullivan NJ, Studebaker AW, Hendey LF, Axel AE, Hall BM. Interleukin-6 is a potent growth factor for ER-α-positive human breast cancer. FASEB J 2007;21:3763-70.
25. Beischlag TV, Taylor RT, Rose DW, et al. Recruitment of thyroid hormone receptor/retinoblastoma-interacting protein 230 by the aryl hydrocarbon receptor nuclear translocator is required for the transcriptional response to both dioxin and hypoxia. J Biol Chem 2004;279:54620-8.
26. Goransson M, Elias E, Stahlberg A, Olofsson A, Andersson C, Aman P. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP β-mediated interleukin 6 expression. Int J Cancer 2005;115:556-60.
27. Chen YH, Tukey RH. Protein kinase C modulates regulation of the CYP1A1 gene by the aryl hydrocarbon receptor. J Biol Chem 1996;271:26261-6.
28. Long WP, Pray-Grant M, Tsai JC, Perdew GH. Protein kinase C activity is required for aryl hydrocarbon receptor pathway-mediated signal transduction. Mol Pharmacol 1998;53:691-700.
29. Reiners JJ, Jr., Cantu AR, Scholler A. Phorbol ester-mediated suppression of cytochrome P450 Cyp1a-1 induction in murine skin: involvement of protein kinase C. Biochem Biophys Res Commun 1992;186:970-6.
30. Angel P, Imagawa M, Chiu R, et al. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell 1987;49:729-39.
31. Lee W, Mitchell P, Tjian R. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. Cell 1987;49:741-52.
32. Molitor JA, Walker WH, Doerre S, Ballard DW, Greene WC. NF-κ B: a family of inducible and differentially expressed enhancer-binding proteins in human T cells. Proc Natl Acad Sci U S A 1990;87:10028-32.
33. Umayahara Y, Kajimoto Y, Fujitani Y, et al. Protein kinase C-dependent, CCAAT/enhancer-binding protein β-mediated expression of insulin-like growth factor I gene. J Biol Chem 2002;277:15261-70.
34. Xiao W, Hodge DR, Wang L, Yang X, Zhang X, Farrar WL. Co-operative functions between nuclear factors NFκB and CCAT/enhancer-binding protein-κ (C/EBPh) regulate the IL-6 promoter in autocrine human prostate cancer cells. Prostate 2004;61:354-70.
35. Reiners JJ, Jr., Scholler A, Bischer P, Cantu AR, Pavone A. Suppression of cytochrome P450 Cyp1a-1 induction in murine hepatoma 1c1c7 cells by 12-O-tetradecanoylphorbol-13-acetate and inhibitors of protein kinase C. Arch Biochem Biophys 1993;301:449-54.
36. Jeong HG. Cytokine-mediated suppression of cytochrome P450 1A1 in Hepa-1c1c7 cells by pokeweed mitogen. Toxicol Lett 2001;119:125-32.
37. Gharavi N, El-Kadi AO. Down-regulation of aryl hydrocarbon receptor-regulated genes by tumor necrosis factor-α and lipopolysaccharide in murine hepatoma Hepa 1c1c7 cells. J Pharm Sci 2005;94:493-506.
38. Tian Y, Ke S, Denison MS, Rabson AB, Gallo MA. Ah receptor and NF-κB interactions, a potential mechanism for dioxin toxicity. J Biol Chem 1999;274:510-5.
39. Marlowe JL, Puga A. Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. J Cell Biochem 2005;96:1174-84.
40. Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007;110:1911-28.
41. Sasser AK, Mundy BL, Smith KM, et al. Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments. Cancer Lett 2007;254:255-64.
42. Karczewska A, Nawrocki S, Breborowicz D, Filas V, Mackiewicz A. Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma. Cancer 2000;88:2061-71.
43. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate 2000;42:186-95.
44. Beischlag TV, Perdew GH. ER α-AHR-ARNT protein-protein interactions mediate estradiol-dependent trans-repression of dioxin-inducible gene transcription. J Biol Chem 2005;280:21607-11.
45. Klinge CM, Kaur K, Swanson HI. The aryl hydrocarbon receptor interacts with estrogen receptor a and orphan receptors COUP-TFI and ERRα1. Arch Biochem Biophys 2000;373:163-74.
46. Stein B, Yang MX. Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-κB and C/EBP β. Mol Cell Biol 1995;15:4971-9.
47. Nettles KW, Gil G, Nowak J, Metivier R, Sharma VB, Greene GL. CBP is a dosage dependent regulator of NF{κ}B suppression by the estrogen receptor. Mol Endocrinol 2008;22:263-72.
48. Baccam M, Woo SY, Vinson C, Bishop GA. CD40-mediated transcriptional regulation of the IL-6 gene in B lymphocytes: involvement of NF-κB, AP-1, and C/EBP. J Immunol 2003;170:3099-108.
49. Faggioli L, Costanzo C, Merola M, et al. Nuclear factor κ B (NF-κB), nuclear factor interleukin-6 (NFIL-6 or C/EBP β) and nuclear factor interleukin-6β (NFIL6-β or C/EBP δ) are not sufficient to activate the endogenous interleukin-6 gene in the human breast carcinoma cell line MCF-7. Comparative analysis with MDA-MB-231 cells, an interleukin-6- expressing human breast carcinoma cell line. Eur J Biochem 1996;239:624-31.
50. Armenante F, Merola M, Furia A, Tovey M, Palmieri M. Interleukin-6 repression is associated with a distinctive chromatin structure of the gene. Nucleic Acids Res 1999;27:4483-90.